What CFOs Need to Know About the 2026 340B Rebate Model and the AHA Lawsuit

The proposed 2026 340B rebate model would replace upfront drug discounts with delayed reimbursement, shifting liquidity and compliance risk directly onto hospitals. For CFOs, this is not just a policy dispute but a fundamental change in cash flow, margin protection, and enterprise risk management—especially for safety-net providers.